Synthesis and evaluation of (S,S)-N,N'-bis-[3-(2,2',6,6'-tetramethylbenzhydryloxy)-2-hydroxy-propyl]-ethylenediamine (S2824) analogs with anti-tuberculosis activity. 2009

Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China.

In order to identify new and potent candidate drugs to treat tuberculosis, a library of compounds was screened, and (S,S)-N,N'-bis-[3-(2,2',6,6'-tetramethylbenzhydryloxy)-2-hydroxy-propyl]-ethylenediamine (S2824) was identified as a hit in the screen. This research discusses our efforts to synthesize and test 30 analogs of this hit for activity against Mycobacterium tuberculosis. Two compounds with homopiperazine ring possess high in vitro activity against drug sensitive and resistant M. tuberculosis with MICs 0.78-3.13 microg/mL (or 1.22-4.88 microM).

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005029 Ethylenediamines Derivatives of ethylenediamine (the structural formula NH2CH2CH2NH2).
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines
D001559 Benzhydryl Compounds Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed. Diphenylmethyl Compounds,Compounds, Benzhydryl,Compounds, Diphenylmethyl
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance

Related Publications

Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
February 2016, Acta crystallographica. Section E, Crystallographic communications,
Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
November 2009, Acta crystallographica. Section E, Structure reports online,
Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
February 1972, Journal of medicinal chemistry,
Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
July 2010, Bioorganic & medicinal chemistry,
Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
November 2009, Acta crystallographica. Section E, Structure reports online,
Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
August 1968, Arzneimittel-Forschung,
Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
April 2018, ACS medicinal chemistry letters,
Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
July 1989, Journal of medicinal chemistry,
Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
May 2001, Acta crystallographica. Section C, Crystal structure communications,
Xuelian Zhang, and Yanwei Hu, and Shudan Chen, and Rusong Luo, and Jun Yue, and Ying Zhang, and Wenhu Duan, and Honghai Wang
January 1995, Chirality,
Copied contents to your clipboard!